Novo Nordisk has turned to Replicate Bioscience’s RNA drug platform in a lucrative research collaboration, marking the latest effort by the big pharma company to diversify its pipeline in the hope of ...

Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team "I am delighted to welcome Rachael to the ...

Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research ...

Replicate, a startup that runs machine learning models in the cloud, today launched out of stealth with $17.8 million in venture capital backing; $12.5 million of the total came from a Series A led by ...

Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability SAN DIEGO, Feb. 7, 2025 /PRNewswire/ -- Replicate Bioscience, a ...

To strengthen its development efforts, Novo Nordisk A/S will collaborate in a deal that could bring Replicate Bioscience Inc. about $550 million. In return, Novo is getting an exclusive, worldwide ...

Replicate Bioscience Inc. and Novo Nordisk A/S have entered into a multiyear research collaboration that will leverage Replicate’s novel self-replicating RNA (srRNA) platform to develop new ...

ROCKVILLE, Md. & SAN DIEGO--(BUSINESS WIRE)--Replicate Bioscience, Inc. (“Replicate”), a privately-held biopharmaceutical company creating novel treatments to prevent drug resistance in cancers, and ...